News Releases
Filter by Year
May 25, 2022
LexaGene is pleased to announce a large veterinary animal health corporation has purchased two MiQLab® Systems for two of their locations.

May 3, 2022
The U.S. Army Combat Capabilities Development Command Chemical Biological Center (DEVCOM Chemical Biological Center) has successfully completed the evaluation of the MiQLab System for biothreat detection.

April 25, 2022
LexaGene is pleased to announce a corporate veterinary reference laboratory has purchased 3 MiQLab® Systems for one of their many locations.

March 29, 2022
To better handle more complex samples, we have recently embedded a new chemistry into our sample preparation cartridge that greatly improves the MiQLab System’s ability to process samples that contain a significant percentage of blood, which is a powerful inhibitor of PCR.

February 23, 2022
The second tranche of the previously announced private placement to Meridian LGH Holdings, LLC has closed.

February 8, 2022
Meridian LGH Holdings LLC, (the “Investor”) has agreed to make an investment in LexaGene for a total of CAD$6,475,000 (approximately USD$4,995,000). The Company and the Investor intend that the investment will occur by way of non-brokered private placement (the “Private Placement”) anticipated to close in two tranches.

January 3, 2022
Today, LexaGene announced purchase orders for MiQLab™ Systems from veterinary clinics in Michigan, Minnesota, and New York.

December 17, 2021
Here are the voting results of the Company’s 2021 Annual General Special Meeting on December 16, 2021 in Vancouver, British Columbia.

November 29, 2021
LexaGene Intends to Pursue Full Panel Pathogen Testing through the FDA

November 15, 2021
Dr. Jane Sykes, BVSc(Hons), PhD, MBA, DipACVIM (Small Animal Internal Medicine) has joined the LexaGene Board of Directors. Dr. Sykes is the Executive Director of Innovation and Entrepreneurship, School of Veterinary Medicine at the University of California, Davis (UC Davis) and Professor of Small Animal Internal Medicine (Infectious Diseases).

1 2 3 15

For Marketing inquiries, please email:

info@lexagene.com

800-215-1824